<h4>Background and aims</h4>GLP-1 receptor agonists (GLP-1RAs) promote significant weight loss, but their impact on muscle mass, strength, and quality in metabolic dysfunction-associated steatotic liver disease (MASLD), a condition prone to muscle impairment, remains uncertain.<h4>Methods</h4>We conducted a systematic review of MEDLINE/PubMed, Embase, and the Cochrane Library up to 2 December 2025. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.